Form 4: NovoCure Director Gabriel Leung Reports Stock Sale and RSU Grant

Director Gabriel Leung of NovoCure Ltd. reports the sale of 964 ordinary shares and the acquisition of 4,053 restricted stock units.

Summary

• On June 4, 2024, Gabriel Leung, a director of NovoCure Ltd., sold 964 ordinary shares at a weighted average price of $23.8851.
• The sale was executed in multiple trades with prices ranging from $23.75 to $24.00.
• On June 5, 2024, Leung acquired 4,053 restricted stock units (RSUs).
• These RSUs are scheduled to vest 100% on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.
• Leung also acquired options to buy 6,229 ordinary shares on June 5, 2024, at an exercise price of $23.13.
• These options will fully vest and become exercisable on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.
• Following these transactions, Leung beneficially owns 78,175 ordinary shares, 83,192 restricted stock units, and options to buy 6,229 ordinary shares.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider trading activity.

Future Outlook

The restricted stock units and options vest on the earlier of the first anniversary of the grant date or the day immediately preceding the Company's 2025 annual general meeting of shareholders.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, providing transparency to investors regarding the trading activities of key personnel. It is common practice for directors and officers to receive stock options and restricted stock units as part of their compensation packages, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotechnology industry, used to incentivize executives and align their interests with long-term shareholder value.
• Vesting schedules, such as the one described in the document (vesting on the earlier of the first anniversary of the grant date or the day before the next annual general meeting), are typical for these types of equity grants.
• Comparing the size of the grant to those of directors at similar companies (e.g., Incyte, Exelixis, or Vertex Pharmaceuticals) would provide further context on the magnitude of this compensation.

Stakeholder Impact

• Shareholders are informed about the director's stock transactions, providing transparency.
• The transactions may have a minor impact on the stock price due to the sale of shares.

Key Dates